A clinical trial of multiple peptides vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS

Yoshihiro Yoshitake; Yasuharu Nishimura; Yusuke Nakamura; Masanori Shinohara

doi:10.1080/2162402X.2015.1022307

A clinical trial of multiple peptides vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS

Oncoimmunology. 2015 Apr 1;4(8):e1022307. doi: 10.1080/2162402X.2015.1022307. eCollection 2015 Aug.

Authors

Yoshihiro Yoshitake¹, Yasuharu Nishimura², Yusuke Nakamura³, Masanori Shinohara¹

Affiliations

¹ Department of Oral and Maxillofacial Surgery; Graduate School of Medical Sciences; Kumamoto University ; Kumamoto, Japan ; Itoh Dent-Maxillofacial Hospital ; Kumamoto, Japan.
² Department of Immunogenetics; Graduate School of Medical Sciences; Kumamoto University ; Kumamoto, Japan.
³ Laboratory of Molecular Medicine; Human Genome Center; Institute of Medical Science; University of Tokyo ; Tokyo, Japan ; Department of Medicine; University of Chicago ; Chicago, IL USA.

Abstract

A phase II clinical trial for head and neck squamous cell cancer (HNSCC) patients using multiple peptides vaccine derived from tumor-associated antigens (TAAs) was performed. The therapy was well tolerated and overall survival was statistically significantly longer in vaccinated patients, and the patients exhibiting cytotoxic T lymphocytes (CTL) responses to multiple peptides exhibited better prognosis.

Keywords: cancer vaccine therapy; cytotoxic T lymphocytes; head and neck squamous cell cancer; multiple peptides vaccine; phase II clinical trial; tumor-associated antigens.

Publication types

Research Support, Non-U.S. Gov't